Teva Says GSK Skinny Label Win Will Have 'Seismic' Impact

By Dani Kass · October 7, 2021, 5:46 PM EDT

The Federal Circuit's second holding that Teva induced doctors to infringe a patent for GlaxoSmithKline's drug Coreg, despite allegedly carving out the only patented-protected treatment from its label, will have a...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

May 16, 2018

Recent Articles By Dani

July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
January 11, 2024
NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse